Compare Hims and Hers Health Inc (HIMS) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Royal Bank of Canada — how do they compare? Hims and Hers Health Inc trades at $28.44 (market cap $6.89B), while Royal Bank of Canada trades at $192.67 (market cap $265.72B). The key difference: Royal Bank of Canada is far larger — about 38.6× Hims and Hers Health Inc's market cap, and Royal Bank of Canada pays a 2.65% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Royal Bank of Canada for 47 Days on average.
| HIMS | RY | |
|---|---|---|
Market Cap | $6.89B | $265.72B |
Volume | 5,446,628 | 756,291 |
Sector | Health | Financials |
52-Week High | $62.76 | $217.87 |
52-Week Low | $14.52 | $143.64 |
Typical Hold Time | 21 Days | 47 Days |
Enterprise Value | $7.60B | $732.82B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $29.54, up 0.24% on the day, with a bullish technical signal from moving averages but mixed earnings performance. Revenue grew to $2.35 billion in 2025, yet the company posted a net loss of $142 million in 2026, reflecting profitability challenges. High valuation ratios like a P/E of 57.14 and negative ROE of -32.03% indicate premium pricing despite weak earnings. Recent news highlights multiple securities class action lawsuits filed in October 2026, creating legal overhangs.
The stock faces headwinds from profitability struggles and legal risks, but analyst consensus remains a Buy with a $32.17 price target, suggesting modest upside. Investment appeal hinges on resolving operational inefficiencies and legal issues to align valuation with fundamentals, while current sentiment is cautious due to recent earnings misses and regulatory scrutiny.
Royal Bank of Canada (RY) trades at $190.56, down 2.95% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $3.07 beating estimates of $2.89 (Zacks Investment Research, August 27, 2026). Revenue growth accelerated to $66.53B in 2025, with net income margin improving to 32.01%. The company maintains a solid dividend payout of $1.76 per share, with the next payment scheduled for November 24, 2026.
RY presents a mixed investment case with strong profitability and dividend stability offset by stretched valuations and bearish technical indicators. The 17.2 P/E ratio suggests fair valuation, while analyst consensus leans neutral with 43% buy ratings. Key risks include macroeconomic sensitivity and competitive pressures in financial services. The stock's current technical weakness near support at $189 may present entry opportunities for long-term investors seeking quality banking exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
